355 related articles for article (PubMed ID: 34362344)
1. Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.
De Caluwé A; Buisseret L; Poortmans P; Van Gestel D; Salgado R; Sotiriou C; Larsimont D; Paesmans M; Craciun L; Stylianos D; Vandekerckhove C; Reyal F; Isabelle V; Eiger D; Piccart M; Romano E; Ignatiadis M
BMC Cancer; 2021 Aug; 21(1):899. PubMed ID: 34362344
[TBL] [Abstract][Full Text] [Related]
2. First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.
De Caluwe A; Romano E; Poortmans P; Gombos A; Agostinetto E; Marta GN; Denis Z; Drisis S; Vandekerkhove C; Desmet A; Philippson C; Craciun L; Veys I; Larsimont D; Paesmans M; Van Gestel D; Salgado R; Sotiriou C; Piccart-Gebhart M; Ignatiadis M; Buisseret L
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056900
[TBL] [Abstract][Full Text] [Related]
3. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Nanda R; Liu MC; Yau C; Shatsky R; Pusztai L; Wallace A; Chien AJ; Forero-Torres A; Ellis E; Han H; Clark A; Albain K; Boughey JC; Jaskowiak NT; Elias A; Isaacs C; Kemmer K; Helsten T; Majure M; Stringer-Reasor E; Parker C; Lee MC; Haddad T; Cohen RN; Asare S; Wilson A; Hirst GL; Singhrao R; Steeg K; Asare A; Matthews JB; Berry S; Sanil A; Schwab R; Symmans WF; van 't Veer L; Yee D; DeMichele A; Hylton NM; Melisko M; Perlmutter J; Rugo HS; Berry DA; Esserman LJ
JAMA Oncol; 2020 May; 6(5):676-684. PubMed ID: 32053137
[TBL] [Abstract][Full Text] [Related]
4. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
Bardia A; Pusztai L; Albain K; Ciruelos EM; Im SA; Hershman D; Kalinsky K; Isaacs C; Loirat D; Testa L; Tokunaga E; Wu J; Dry H; Barlow W; Kozarski R; Maxwell M; Harbeck N; Sharma P
Ther Adv Med Oncol; 2024; 16():17588359241248336. PubMed ID: 38686016
[TBL] [Abstract][Full Text] [Related]
5. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
6. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Loibl S; Untch M; Burchardi N; Huober J; Sinn BV; Blohmer JU; Grischke EM; Furlanetto J; Tesch H; Hanusch C; Engels K; Rezai M; Jackisch C; Schmitt WD; von Minckwitz G; Thomalla J; Kümmel S; Rautenberg B; Fasching PA; Weber K; Rhiem K; Denkert C; Schneeweiss A
Ann Oncol; 2019 Aug; 30(8):1279-1288. PubMed ID: 31095287
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.
Chen J; Han Y; Hu Y; Feng X; Meng X; Guo S; Sun C; Chen G; Li K
BMJ Open; 2023 May; 13(5):e067767. PubMed ID: 37253491
[TBL] [Abstract][Full Text] [Related]
8. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Bozorgmehr F; Chung I; Christopoulos P; Krisam J; Schneider MA; Brückner L; Mueller DW; Thomas M; Rieken S
BMC Cancer; 2020 Aug; 20(1):806. PubMed ID: 32842974
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).
Hanna CR; O'Cathail SM; Graham JS; Saunders M; Samuel L; Harrison M; Devlin L; Edwards J; Gaya DR; Kelly CA; Lewsley LA; Maka N; Morrison P; Dinnett L; Dillon S; Gourlay J; Platt JJ; Thomson F; Adams RA; Roxburgh CSD
Radiat Oncol; 2021 Aug; 16(1):163. PubMed ID: 34446053
[TBL] [Abstract][Full Text] [Related]
10. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
Kuon J; Hommertgen A; Krisam J; Lasitschka F; Stenzinger A; Blasi M; Bozorgmehr F; Maenz M; Kieser M; Schneider M; Thomas M
Trials; 2020 Apr; 21(1):352. PubMed ID: 32321565
[TBL] [Abstract][Full Text] [Related]
12. Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma-randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol.
Modesto A; Tougeron D; Tremolières P; Ronchin P; Jouve AD; Leignel DA; Vendrely V; Riou O; Martin-Babau J; Le Sourd S; Mirabel X; Leroy T; Huguet F; Montaigne L; Baumgaertner I; Deslandres M; Moyal E; Seva C; Selves J; Otal P; Pezzella V; Guimbaud R; Filleron T; Quéro L
BMC Cancer; 2023 Oct; 23(1):966. PubMed ID: 37828434
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Buisseret L; Loirat D; Aftimos P; Maurer C; Punie K; Debien V; Kristanto P; Eiger D; Goncalves A; Ghiringhelli F; Taylor D; Clatot F; Van den Mooter T; Ferrero JM; Bonnefoi H; Canon JL; Duhoux FP; Mansi L; Poncin R; Barthélémy P; Isambert N; Denis Z; Catteau X; Salgado R; Agostinetto E; de Azambuja E; Rothé F; Craciun L; Venet D; Romano E; Stagg J; Paesmans M; Larsimont D; Sotiriou C; Ignatiadis M; Piccart-Gebhart M
Nat Commun; 2023 Nov; 14(1):7018. PubMed ID: 37919269
[TBL] [Abstract][Full Text] [Related]
14. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
15. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
[TBL] [Abstract][Full Text] [Related]
16. WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.
Hofmann D; Nitz U; Gluz O; Kates RE; Schinkoethe T; Staib P; Harbeck N
Trials; 2013 Aug; 14():261. PubMed ID: 23958221
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Lieverse RIY; Van Limbergen EJ; Oberije CJG; Troost EGC; Hadrup SR; Dingemans AC; Hendriks LEL; Eckert F; Hiley C; Dooms C; Lievens Y; de Jong MC; Bussink J; Geets X; Valentini V; Elia G; Neri D; Billiet C; Abdollahi A; Pasquier D; Boisselier P; Yaromina A; De Ruysscher D; Dubois LJ; Lambin P
BMC Cancer; 2020 Jun; 20(1):557. PubMed ID: 32539805
[TBL] [Abstract][Full Text] [Related]
18. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
19. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
Kuemmel S; Harper-Wynne C; Park YH; Franke F; de Laurentiis M; Schumacher-Wulf E; Eiger D; Heeson S; Cardona A; Özyilkan Ö; Morales-Vàsquez F; Metcalfe C; Hafner M; Restuccia E; O'Shaughnessy J
BMC Cancer; 2024 May; 24(1):641. PubMed ID: 38789924
[TBL] [Abstract][Full Text] [Related]
20. Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer.
Sinn BV; Loibl S; Hanusch CA; Zahm DM; Sinn HP; Untch M; Weber K; Karn T; Becker C; Marmé F; Schmitt WD; Müller V; Schem C; Treue D; Stickeler E; Klauschen F; Burchardi N; Furlanetto J; van Mackelenbergh M; Fasching PA; Schneeweiss A; Denkert C
Clin Cancer Res; 2021 May; 27(9):2584-2591. PubMed ID: 33593886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
